Dihydralazine

Dihydralazine Overview

Dihydralazine (chemically designated as 1,4-dihydrazinophthalazine; chemical formula C8H10N6) is a synthetic hydrazinophthalazine derivative and direct-acting arteriolar vasodilator. Chemically, it belongs to the class of organic compounds known as phthalazines within the diazanaphthalenes sub-class of organoheterocyclic compounds. Structurally, it consists of a benzene ring fused to a pyridazine ring forming a phthalazine core, substituted with two hydrazine functional groups at positions 1 and 4.

In cardiovascular pharmacology, hypertension management, and nephrology, Dihydralazine functions as an antihypertensive agent and vascular smooth muscle relaxant (ATC code C02DB01 for hydrazinophthalazine derivatives). Formulated as dihydralazine sulfate in oral tablets and parenteral solutions for injection (marketed under international trade names such as Nepresol and Adepress), it is indicated for the management of severe essential hypertension, hypertensive crises, refractory hypertension in kidney disease, and pregnancy-induced hypertensive emergencies such as pre-eclampsia. By directly relaxing vascular smooth muscle in resistance arterioles, it decreases systemic vascular resistance and lowers blood pressure. Although widely utilized in European, Latin American, and Asian healthcare systems, Dihydralazine is not approved for pharmaceutical distribution by the US FDA, which approves its close structural analog, hydralazine.

What Is Dihydralazine and How Does It Work?

Dihydralazine acts primarily through direct relaxation of vascular smooth muscle in arterial resistance vessels, causing reduction of total peripheral resistance and blood pressure.

Its primary chemical, physiological, and antihypertensive mechanisms include:

• Direct Arteriolar Smooth Muscle Relaxation: Dihydralazine selectively relaxes smooth muscle in peripheral arterioles rather than venous capacitance vessels. This selective arterial dilation drops systemic vascular resistance (afterload) without altering venous return or causing significant orthostatic hypotension.
• Intracellular Calcium Modulation: It inhibits calcium ion influx and blocks intracellular calcium release from the sarcoplasmic reticulum in vascular smooth muscle cells, inhibiting actin-myosin cross-bridge formation.
• Reflex Sympathetic Activation: Significant reductions in systemic blood pressure trigger baroreceptor-mediated sympathetic reflexes, leading to compensatory tachycardia, increased stroke volume, elevated cardiac output, and increased plasma renin activity.
• Renal Perfusion Preservation: By selectively dilating renal resistance vessels, Dihydralazine maintains or increases renal blood flow and glomerular filtration rate despite marked drops in systemic arterial pressure.
• Enzyme Interactions: It acts as an inhibitor of copper-containing diamine oxidase and human myeloperoxidase, which may contribute to its metabolic degradation pathways and tissue accumulation profiles.

Is Dihydralazine FDA Approved?

Dihydralazine sulfate has not been submitted or approved for marketing in the United States by the US FDA, classifying its current approval status as Not Approved.

What Is Dihydralazine Used For?

• Management of severe essential hypertension and refractory arterial hypertension.
• Treatment of hypertensive emergencies and urgency states requiring rapid blood pressure reduction.
• Treatment of pregnancy-induced hypertension, pre-eclampsia, and eclampsia.
• Management of hypertension secondary to renal parenchymal disease or chronic kidney disease.

Before Taking Dihydralazine: Contraindications & Precautions

Do not administer Dihydralazine to patients with idiopathic systemic lupus erythematosus (SLE), severe tachycardia, heart failure with high cardiac output, aortic dissection, or severe coronary artery disease (such as unstable angina or recent myocardial infarction). Exercise caution in patients with renal impairment, as reduced clearance can accelerate drug accumulation and increase the risk of drug-induced lupus syndrome.

Who Should Not Take Dihydralazine?

• Patients with known idiopathic systemic lupus erythematosus (SLE) or autoimmune connective tissue disorders.
• Individuals with severe coronary artery disease, unstable angina, or recent acute myocardial infarction.
• Patients with dissecting aortic aneurysm or severe mitral valve rheumatic heart disease.
• Individuals with severe tachyarrhythmias or heart failure with high cardiac output.
• Individuals with known hypersensitivity to Dihydralazine, hydralazine, or phthalazine derivatives.

Dihydralazine, Pregnancy & Safety

Dihydralazine crosses the placental barrier. It has been used extensively in clinical practice across Europe to treat severe hypertension in pregnancy, pre-eclampsia, and eclampsia without evidence of overt teratogenicity. However, rapid intravenous administration can cause maternal hypotension and secondary fetal distress or hypoxia. Administer during pregnancy only under close maternal-fetal monitoring. Dihydralazine is excreted in small amounts into human breast milk; monitor nursing infants for adverse hypotensive effects.

Tell Your Doctor Before Taking Dihydralazine

Inform your physician if you have a history of heart disease, prior heart attack, stroke, kidney dysfunction, liver disease, or a family history of slow acetylator metabolic status.

Dihydralazine Dosage & Administration

Formulated as oral tablets containing 12.5 mg, 25 mg, or 50 mg of dihydralazine sulfate, and parenteral injection ampoules containing 12.5 mg/mL or 25 mg/mL.

Standard Dihydralazine Dosing

• Oral Hypertension Dosing (Adults): The typical starting dose is 12.5 mg to 25 mg orally twice daily, increased gradually to a maintenance dose of 50 mg twice daily (maximum 200 mg/day total) based on blood pressure response.
• Parenteral Hypertensive Crisis / Pre-Eclampsia Dosing: Administered as 6.25 mg to 12.5 mg by slow intravenous injection over 2 to 5 minutes, or as a continuous intravenous infusion at 5 mg to 15 mg per hour, titrated to maintain target blood pressure.

How Dihydralazine Is Administered

• Take oral tablets with a glass of water, preferably with or immediately after meals to ensure consistent systemic absorption.
• Intravenous injections should be administered slowly with continuous blood pressure and electrocardiogram monitoring.

Dihydralazine Clinical Efficacy & Safety Profile

Dihydralazine is a highly effective, rapid-acting arterial vasodilator that reliably lowers systolic and diastolic blood pressure in severe or refractory hypertension. Because direct arterial vasodilation triggers strong reflex sympathetic stimulation (tachycardia, palpitations, fluid retention), it is most clinically effective when combined with a beta-blocker (to control heart rate) and a diuretic (to prevent sodium and water retention). Long-term high-dose therapy carries a dose-dependent risk of drug-induced lupus erythematosus, particularly in slow hepatic N-acetyltransferase (NAT2) acetylators.

Dihydralazine Side Effects & Safety Profile

Common adverse effects include reflex tachycardia, palpitations, flushing, headache, nasal congestion, fluid retention, edema, nausea, and dizziness. Serious adverse risks include drug-induced lupus erythematosus (DILE), severe angina, myocardial infarction, profound hypotension, and peripheral neuropathy. Holds no FDA Black Box Warning due to unapproved status.

Common Dihydralazine Side Effects

• Cardiovascular & Vascular: Reflex rapid heart rate (tachycardia), heart palpitations, facial flushing, peripheral edema, and postural dizziness.
• Neurological & Gastrointestinal: Throbbing headache, nasal congestion, nausea, vomiting, diarrhea, and fatigue.

Serious Dihydralazine Adverse Events

• Drug-Induced Lupus Erythematosus (DILE): Autoimmune syndrome characterized by arthralgia, fever, pericarditis, pleuritis, and positive antinuclear antibodies (ANA), occurring predominantly at high doses (> 100 mg/day) and in slow acetylators.
• Myocardial Ischemia & Angina: Severe reflex tachycardia and increased myocardial oxygen demand can precipitate acute angina pectoris or myocardial infarction in patients with underlying coronary artery disease.
• Peripheral Neuropathy: Pyridoxine (vitamin B6) deficiency-induced numbness, tingling, and paresthesias in extremities following long-term use.

Managing Dihydralazine Side Effects

Co-administer a beta-blocker (e.g., metoprolol, bisoprolol) to control reflex tachycardia and a loop or thiazide diuretic to manage fluid retention. Supplemental pyridoxine (vitamin B6) may be given to prevent peripheral neuropathy. Discontinue therapy if ANA titers rise and clinical lupus symptoms appear.

Dihydralazine Drug Interactions & What to Avoid

Co-administration with other hypotensive or vasodilatory drugs amplifies blood pressure reduction.

Dihydralazine Drug-Drug Interactions

• Antihypertensives & Nitrates (e.g., ACE Inhibitors, ARBs, Nitroprusside): Additive hypotensive effects; dose adjustments are required to prevent severe orthostatic hypotension or shock.
• Monoamine Oxidase Inhibitors (MAOIs): Concurrent use can cause profound, unpredictable blood pressure drops.
• NSAIDs (e.g., Indomethacin, Ibuprofen): Nonsteroidal anti-inflammatory drugs inhibit renal prostaglandin synthesis, reducing the antihypertensive efficacy of Dihydralazine.
• Beta-Blockers (e.g., Propranolol, Metoprolol): Beneficial combination that prevents reflex tachycardia, but enhances bioavailability and systemic exposure of both agents.

Dihydralazine, Food & Alcohol

Food enhances systemic bioavailability. Avoid alcohol consumption, as alcohol causes peripheral vasodilation and can exacerbate Dihydralazine-induced dizziness, severe hypotension, and fainting.

Dihydralazine: Missed Dose, Overdose & Storage

Take missed oral doses as soon as remembered unless near the next dose. Overdose produces profound hypotension and shock. Store formulations at room temperature (15°C–25°C).

Missed Dose of Dihydralazine

Take the missed tablet as soon as remembered. If it is almost time for your next scheduled dose, skip the missed dose and return to your normal dosing schedule. Do not take two doses at once.

Dihydralazine Overdose & Emergency

Acute overdose causes severe hypotension, pronounced reflex tachycardia, cardiac arrhythmias, generalized headache, skin flushing, myocardial ischemia, and shock. Emergency management involves immediate Trendelenburg positioning, intravenous fluid administration to expand volume, vasopressors (such as norepinephrine), and continuous cardiac monitoring.

How to Store Dihydralazine

Store tablets and injection ampoules at controlled room temperature between 15°C and 25°C (59°F to 77°F). Protect from direct light, excessive heat, and moisture. Keep strictly out of reach of children.

Dihydralazine Patient Management & Monitoring

Requires routine monitoring of blood pressure, heart rate, renal function, complete blood count, and antinuclear antibody (ANA) status.

Tests Before Starting Dihydralazine

Baseline blood pressure, resting heart rate, complete blood count (CBC), serum creatinine, estimated glomerular filtration rate (eGFR), baseline antinuclear antibody (ANA) titer, and acetylator phenotype testing if available.

Monitoring During Dihydralazine Treatment

Frequent blood pressure and heart rate monitoring; periodic CBC and ANA titers every 6 to 12 months during long-term maintenance; checking for signs of joint pain, fever, or fluid retention.

Dihydralazine Do’s and Don’ts

• Do take Dihydralazine consistently with or after meals to ensure stable absorption.
• Do use concurrently with a beta-blocker and diuretic as prescribed to prevent side effects.
• Do report persistent joint pain, unexplained fever, or chest pain to your physician immediately.
• Do not stop taking Dihydralazine abruptly, as rebound hypertension can occur.
• Do not drive or operate machinery if you feel dizzy or lightheaded upon standing.

Frequently Asked Questions

References

• DrugBank Database – Dihydralazine Clinical Profile (DB12945)
• Classyfire Database – Phthalazines / Organoheterocyclic Compounds Taxonomy Profile
• European Pharmacopoeia / Swissmedic Drug Information – Nepresol (Dihydralazine Sulfate)

Legal Disclaimer

The detailed medical and chemical information provided on this specific web page is intended strictly for educational and informational purposes regarding complex pharmacological mechanisms. It absolutely does not constitute professional medical advice, medical diagnosis, or specific treatment recommendations. Always consult a licensed healthcare provider before making any personal decisions regarding complex medical conditions, medication adjustments, or dietary changes.